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Abstract





ated  the  efficacy  of  LDL  reduction,  the  rate  of  adverse 
events, and the progression of atherosclerosis.
Methods  Between  July  1992  and  April  2009,  we  per-




tricular  function  and  valvular  status was  checked  prior  to 
the first apheresis therapy and at  the end of the individual 
HELP program. Blood samples were taken directly before 
and  after  each  therapy.  Blood  count,  electrolytes,  total 
cholesterol,  LDL–C,  high  density  lipoprotein  (HDL–C), 
triglycerides,  lipoprotein  (a)  (Lp(a)),  and  fibrinogen were 
measured. Adverse events were documented weekly.
Results  We  evaluated 27 patients  (19 men) with FH  (age 





patients  had  a  three  vessel  disease  (VD;  25.9%  two VD, 
25.9% one VD) and 7.4% had a peripheral arterial occlusive 




The  patients  received  1.2 ± 1.6  (range  0–5)  PCI  during 





HELP  apheresis  were  rare.  This  data  is  in  line  with  the 
















































choices  to  improve  lipid profiles. However,  some patients 
with  homozygous  or  severe  heterozygous  FH  cannot  be 
treated sufficiently by drug therapy and diet and they require 
additional extracorporeal treatment [5]. LDL-C apheresis is 
a  last  treatment  option  for  hypercholesterolemic  patients 
resistant to conservative lipid-lowering therapy [6–9].
There  are  different  methods  of  eliminating  LDL–C 
by  lipid  apheresis.  They  are  mainly  based  on  adsorption 
(DALI = Direct Adsorption  of Lipoproteins  (Fresenius,  St. 
Wendel, Germany);  IMAL = Immuno Adsorption  of  Lipo-
proteins  (Baxter,  Munich,  Germany);  and  DSA = Dextran 
Sulphate  Adsorption  (Kaneka,  Osaka,  Japan)).  Another 
method focuses on Membrane Differential Filtration (MDF; 
Diamed,  Cologne, Germany). The method  of Heparin-in-








The  suggested  efficacy  targets  for  apheresis  in  hetero-
zygote  FH  patients  are  a  reduction  of  at  least  60%  from 
baseline LDL-C levels [12]. In addition to its efficacy, the 





















Between  July  1992  and April  2009,  we  performed  8,533 
HELP apheresis  therapies  in  patients with FH. Data were 
analyzed retrospectively.
Inclusion  criteria were  FH with  insufficient  lipidologi-
cal status under optimal drug therapy and diet and at least 
50 HELP  therapies. The cardiovascular  risk  factors  (nico-
tine, arterial hypertension, diabetes mellitus, FH) and car-
diovascular  interventional  history  prior  to  the  first  HELP 
application  were  evaluated.  The  left  ventricular  function 
and valvular status were checked prior to the first apheresis 
therapy and at the end of the individual apheresis program. 




rol,  LDL–C,  high  density  lipoprotein  (HDL–C),  triglyce-
rides, Lp(a),  and fibrinogen were measured. Lipidological 
analysis was performed using the Architect ci8200 system 
(Abbott).  Cholesterol  was  measured  by  enzymatic  assay. 
Fibrinogen was measured using the Sysmax CA 7000 (Sie-












HELP works  on  the  principle  of  specific  precipitation  of 
LDL-C, Lp(a),  and fibrinogen at  an  acidic pH  in  the pre-
sence  of  heparin.  The  patient’s  blood  is  separated  from 
the corpuscular blood elements. The plasma is then mixed 
with a sodium acetate buffer (pH 4.85) and heparin. These 












The  statistical  analyses  were  carried  out  using  SPSS 
for Windows,  version  17.0  (SPSS  Inc., U.S.A.).  Standard 
deviation was chosen as measure of dispersion. Results are 
given as mean values ± SD.
Regarding  their  normal  distribution,  the  continuous 




of  the samples,  tests  for normally distributed samples and 
nonparametric  tests  for  non-normally  distributed  samples 
were used.





















stroke  and  developed  CHD  afterwards.  The mean  age  of 
the patients at  the  time of CAD diagnosis was 43.8 ± 10.6 
years (range between 13 and 65 years). When starting the 
individual  apheresis  program,  44.4%  had  a  three  vessel 
disease  (VD;  25.9%  two VD,  25.9% one VD);  7.4%  had 
an additional peripheral arterial occlusive disease treated by 
angioplasty and 44% had coronary bypass graft operation 





nary  intervention  (PCI).  One  patient  (3.7%)  had  1,  three 




Prior  to  initial  apheresis  treatment,  echocardiography 
revealed  a  good  left  ventricular  function with  an  ejection 
fraction (EF) > 55% in 85.2% (EF 40–50: 3.7%; EF 30–40: 
3.7%,  EF < 30:  7.4%). On  follow-up,  23  patients  (85.2%) 
presented  with  the  same  EF,  2  patients  (7.4%)  showed  a 
worsened EF, 2 patients (7.4%) with an improved EF.
Prior to initial application of HELP therapy, the choles-
terol  levels were  significantly  increased  in  all  individuals 
despite  drug  therapy.  Total  cholesterol  was  308 ± 96  mg/
dl  (LDL-C  223 ± 96 mg/dl,  HDL-C  52 ± 16 mg/dl,  trigly-





nation  of  LDL-C  (measurement  immediately  before  and 
Patient No. Start of HELP End of HELP Number of procedures
  1 16.12.1998 12.01.2004 226
  2 25.04.2001 18.02.2004 68
  3 16.10.1992 20.09.1996 185
  4 02.02.1996 08.04.2009 631
  5 14.03.2007 07.04.2009 101
  6 09.11.1994 26.05.1998 50
  7 25.04.2007 15.04.2009 93
  8 11.11.2005 03.04.2009 111
  9 11.12.2003 26.10.2007 67
10 03.08.1999 09.04.2009 419
11 30.06.1992 15.04.2009 758
12 08.07.1992 14.04.2009 751
13 10.03.1994 04.05.2005 527
14 26.04.2007 15.04.2009 91
15 11.02.2003 15.04.2009 291
16 17.01.2007 14.04.2009 116
17 21.04.1994 15.04.2009 686
18 05.05.1994 16.01.2004 472
19 11.01.1993 14.04.2009 790
20 03.03.2005 14.04.2009 56
21 23.05.2005 06.04.2009 169
22 17.05.1999 29.03.2004 230
23 15.04.1996 08.04.2009 437
24 16.09.2003 08.04.2009 249
25 16.04.1998 17.01.2001 65
26 05.05.1998 09.04.2009 463








All  patients  were  on  CSE  inhibitor  before  the  initial 
HELP  therapy  (simvastatin 51.9%;  atorvastatin 37%, pra-










































































































































































































































Recently  published  data  state  that LDL-C  apheresis  is  an 
approved medical therapy for patients who have not reached 




Besides  the  positive  effects  on decreased  susceptibility 
of LDL-C to oxidation, it is also described in the literature 
that  HELP  apheresis  can  improve myocardial  blood  flow 





increasing  antiischemic,  antithrombotic,  and  antiprolifera-
tive  effects. Hence,  the  low  rate  of  cardiovascular  events 




nary  intervention  can  be  traced  back  to  improved micro-
circulatory status and the reduced susceptibility of LDL to 
oxidation. However, this finding might be influenced by the 
very  high  frequency  of  “patient/doctor  contacts”  and  the 
resulting intensive monitoring of complaints. To provide an 





loss  and  peripheral  arterial  disease.  [21,  22]. The  import-
ant mechanism of  the positive effects of apheresis  is  sup-
posed to be a reduced viscosity of the blood because of the 
reduction  in  LDL-C  and  fibrinogen.  Since  fibrinogen,  in 















of  this finding on  the progress of atherosclerosis  since all 
individuals  also  suffer  from  FH. Hence,  further  trials  are 
needed to find definite answers concerning the role of ele-
vated Lp(a) levels.








zed  effects  are  to  protect LDL-C  from oxidation,  the  ini-
tiation of mobilization of cholesterol from the arterial wall 
and  the  decrease  in  endothelial  cell  adhesion  molecules. 


















































































atherosclerosis  as  there was  no myocardial  infarction  and 
a low coronary intervention rate in our patients. Apheresis 
also seems to be a therapeutic option in noncardiac diseases 
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